May 9, 2025 06:57 AM EDT

Corvus' early-phase atopic dermatitis data prompt stock rally

Max Gelman

Senior Editor

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price $CRVS up by as much as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Intellia reports case of liver toxicity in ATTR gene editing study

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation